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Background: Low-platelet reactivity is associated with increased thrombotic complications in patients requiring dual anti-platelet therapy (DAPT). 
DAPT related bleeding complications predict greater mortality and major adverse cardiac events (MACE). Point-of-care testing of platelet function 
may yield insight to the risk of DAPT related bleeding.
Methods: Using a prospective drug-eluting stent (DES) registry, we retrospectively abstracted the bleeding events from patients with assessment of 
clopidogrel responsiveness using the VerifyNow (Accumetrics, San Diego) point-of-care assay.
Subjects were divided into 4 groups according to post-treatment PY12 reaction units (PRU) with the 1st quartile defined as low on-treatment 
reactivity. Major bleeding was defined as intracranial, intraocular or retroperitoneal hemorrhage, overt blood loss resulting in a decrease in 
hemoglobin (Hb) ≥3g/dL, any decrease in Hb ≥ 4g/dL, or transfusion of ≥ 2 units of blood.
Results: The characteristics of the 859 enrolled patients are described in Table 1a. There was no difference in major bleeding in 1st, 3rd and 4th 
quartiles (Table 1b) with relatively low rate of events in the 2nd quartile. Minor bleeding did not vary significantly amongst quartiles.
Conclusions: Low on-treatment reactivity to clopidogrel does not predict bleeding events and is not useful for 
assessing bleeding risk. Alternative tools for assessing bleeding risk are required to tailor antiplatelet therapy for patients. 
